Presented Additional Supportive Preclinical Data for Lead Candidate GT-02287 at Recent Medical Meetings Further Validating Therapeutic Potential and Clinical Utility in Parkinson’s Disease and Gaucher Disease BETHESDA, Md., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small...
BETHESDA, Md., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced that members of management will participate in a fireside chat at the 2022 BTIG Biotechnology Conference on Tuesday, August 9 at 12 p.m. ET and host investor meetings. The...
BETHESDA, Md., June 02, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced that the company’s Chief Operating Officer, Matthias Alder, will present and host one-on-one meetings at the Jefferies Healthcare Conference taking place June 8-10 in New York, NY....
BioSpace
Biopharma is Tackling Misfolding Proteins in Parkinson’s Disease
|
Parkinsons News Today
STAR Compounds Show Potential to Treat GBA1-linked Parkinson’s
|
Neurology Live
A New Approach to Protein Misfolding in Parkinson Disease
|
August, 2022
|
Jan 01, 2021
|
November 11, 2021
|
June 10 2022
|
May 24 2022
|
March 29-30 2022
|